Mannin Research to Participate at ARVO 2016 Meeting

NEW YORK - May 2, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company announces that its technology partner Mannin Research Inc. will be attending the Association for Research in Vision and Ophthalmology (ARVO), which takes place from May 1-5, 2016 in Seattle Washington. Mannin Research executives will be meeting with its vendors and research partners. The meeting provides organizations the opportunity to further explore business development goals and other collaborative opportunities for the MAN-01 program for treatment of glaucoma.

The ARVO annual meeting is the largest gathering of eye and vision researchers in the world. The annual meeting runs from May 1st to 5th at the Washing State Convention Center in Seattle, Washington, attracting over 11,000 attendees from more than 75 countries.

Mannin's CEO, Dr. George N. Nikopoulos stated: "We are very pleased to be attending the meeting. We are looking forward to engaging in meaningful research discussions and exploring possible collaboration opportunities with other innovative groups in attendance."

Announces Additional High Grade Underground Results At Las Chispas; Commencement of Surface Drilling Program

Vancouver - April 28, 2016 (Investorideas.com Newswire) SilverCrest Metals Inc. (TSXV: $SIL.V) ("SilverCrest" or the "Company") is pleased to announce additional results from the underground channel sampling program and the commencement of a surface drilling program at its Las Chispas Project ("Las Chispas") located in Sonora, Mexico , as previously announced on March 2, 2016. Las Chispas is in a prolific mining area with nearby precious metal producers. Historical reports indicate the presence of 14 veins in the district of which only three (Las Chispas, William Tell and Babicanora) have been previously mined extensively in the early 1900s, but none of which appear to have been drilled.

CEO Pens Management Piece Featured in Life Science Leader

NEW YORK - April 28, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company reports the Company's CEO was featured in an article he wrote on venture capital titled Accelerators Enter When VCs Fear To Tread:

http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001

Life Science Leader magazine is an essential business journal for life science executives who work for everything from emerging biotechs to Big Pharmas. Their content is designed to inform readers of industry best practices and motivate them to implement those practices in their businesses.

Each month, Life Science Leader features interviews with executives from the leading pharma and biotech companies, including Pfizer, Merck, Daiichi Sankyo, Genentech, Genzyme, Eli Lilly, and Janssen, as well as the FDA and more. This exclusive thought leadership provides an in-depth look into industry trends and hot topics that will impact the growth of the pharma and biopharma markets. As the market is continually growing and innovating, these insights provide readers with actionable information and strategies to implement when navigating the evolving clinical, manufacturing, entrepreneurial, and regulatory landscapes.

Tech Q&A: CTO of Gopher Protocol (OTCQB: GOPH) Explains How the Guardian Patch Could Potentially Save Your Life

New Mobile Tracking Tech Will Track and Protect Anything You Care About; With or Without GPS

PERRIS, California, Point Roberts WA, April 28, 2016 - Investorideas.com , a global news source covering tech stocks interviews Danny Rittman, CTO of  Gopher Protocol Inc. (OTCQB:GOPH) to learn about its licensed technology, the Guardian Patch, aiming to hit consumer markets in 2017.

The Guardian Patch, under development, is a unique location technology that works with or without GPS. It is a stick-on tracking device that protects and tracks everything from a phone to a loved- one or a pet. Danny shares its history, current status and how the Guardian Patch could potentially save your life in the future.